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Abstract 94 
 95 
 There is an increasing need of new bio-analytical methodologies with enough sensitivity, 96 
robustness and resolution to cope with the analysis of a large number of analytes in complex 97 
matrices in short analysis time. For this purpose, all steps included in any bio-analytical method 98 
(sampling, extraction, clean-up, chromatographic analysis and detection) must be taken into 99 
account to achieve good and reliable results with cost-effective methodologies. The purpose of 100 
this review is to describe the state-of-the-art of the most employed technologies in the period 101 
2009-2012 to achieve fast analysis with liquid chromatography coupled to mass spectrometry 102 
(LC-MS) methodologies for bio-analytical applications. Current trends in fast liquid 103 
chromatography involve the use of several column technologies and this review will focus on the 104 
two most frequently applied: sub-2 µm particle size packed columns to achieve ultra high 105 
pressure liquid chromatography (UHPLC) separations and porous-shell particle packed columns 106 
to attain high efficiency separations with reduced column back-pressures.  107 
 Additionally, recent automated sample extraction and clean-up methodologies to reduce 108 
sample manipulation, variability and total analysis time in bio-analytical applications such as on-109 
line solid phase extraction coupled to HPLC or UHPLC methods, or the use of other approaches 110 
such as molecularly imprinted polymers, restricted access materials, and turbulent flow 111 
chromatography will also be addressed. The use of mass spectrometry and high or even ultra-high 112 
resolution mass spectrometry to reduce sample manipulation and to solve ion suppression or ion 113 
enhancement and matrix effects will also be presented. The advantages and drawbacks of all 114 
these methodologies for fast and sensitive analysis of biological samples are going to be 115 
discussed by means of relevant applications. 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
1. Introduction 125 
 126 
 The need of high-throughput separations in bio-analytical applications able to cope with 127 
the analysis of a large number of analytes in very different and complex matrices has increased 128 
considerably in the last years. The main objective of any laboratory, including bio-analytical 129 
ones, is to develop reliable and efficient procedures to perform both qualitative and quantitative 130 
analysis with cost-effective methodologies with reduced analysis time. HPLC appears as the most 131 
common approach to solve multiple analytical problems, as it is able to separate quite 132 
complicated mixtures of analytes with different molecular weights as well as different polarities 133 
and acid-base properties. However conventional HPLC alone do not solve all the analytical 134 
problems related to bio-analytical applications and will not always satisfy the need of reducing 135 
the total analysis time in a field with a huge variety of analytes and sample matrices but also with 136 
an increased demand on fast analytical results. Challenges in bio-analytical laboratories include 137 
development of fast LC-MS methods able to separate closely related compounds (e.g. analytes 138 
and metabolites) from endogenous components. Developments in LC-MS and related techniques 139 
has been recently reviewed [1], by giving an overview of recent developments in the last decade 140 
about mass analyzers, ionization techniques, fast LC-MS, LC-MALDI-MS, ion mobility 141 
spectrometry, as well as emerging mass spectrometric approaches complementary to LC-MS. 142 
Additionally, several bio-analytical methods include monitoring of drugs in a variety of 143 
biological matrices in order to evaluate their pharmacokinetics, to establish appropriate dosages, 144 
or to determine drugs, drugs of abuse and their metabolites in forensic analysis. Many of these 145 
methods are required to obtain results very fast in order to take medical, forensic or legal 146 
decisions, and at very low concentration levels because of, for instance, the bioavailability of 147 
many of these drugs, the application of low doses or a fast elimination of the drugs due to 148 
excretion or metabolism, between others. The final objective consists of developing bio-149 
analytical methods that meets the rigorous criteria set by validation guidelines in terms of 150 
selectivity, accuracy (trueness and precision) and linearity  [2], but also guaranteeing 151 
confirmation of target and the identification of related and new compounds [3]. 152 
 Nowadays, there are several approaches in HPLC methods which enable the reduction of 153 
the analysis time without compromising resolution and separation efficiency such as the use of 154 
monolithic columns [4-7] or high temperature liquid chromatography [8-10]. But among them the 155 
main approach, including bio-analytical applications, to achieve high-throughput separations is 156 
the use of ultra-high pressure liquid chromatography (UHPLC) using sub-2 µm particle packed 157 
columns [11,12]. Additionally, porous shell columns (packed with sub-3 µm superficially porous 158 
particles) are starting to be used for fast chromatographic separations [13-16]. 159 
 Despite the advances in chromatographic separations techniques, the complexity of 160 
biological sample matrices makes direct analysis by HPLC problematic. For instance, irreversible 161 
adsorption of proteins in the stationary phase can occur, producing loss of column efficiency and 162 
increase in column backpressure. Therefore, the use of ultra-fast separations is not enough to 163 
develop fast analytical methods in bio-analysis, and sample treatment is still one of the most 164 
important parts of the analytical process; effective sample preparation is essential for achieving 165 
good analytical results. Sample preparation has usually been performed using protein 166 
precipitation (PPT), liquid-liquid extraction (LLE) or solid phase extraction (SPE), but these 167 
procedures are in general laborious and time-consuming. An ideal sample preparation method 168 
would be fast, accurate, precise and keep sample integrity. Over the last years, considerable 169 
efforts have been made to develop modern approaches in sample treatment techniques that enable 170 
the reduction of analysis time without compromising the integrity of the extraction process [17]. 171 
The use of on-line SPE, which minimizes sample manipulation and provides both high pre-172 
concentration factors and recoveries, is an increasingly powerful and rapid technique used to 173 
improve the sample throughput and overcome many of the limitations associated with the 174 
classical off-line SPE procedure. Higher specificity and selectivity together with satisfactory 175 
extraction efficiency can be obtained using sorbents based on molecularly imprinted polymers 176 
(MIPs). SPE based on MIPs is a highly attractive and promising approach for matrix clean-up, 177 
enrichment and selective extraction of analytes in such kind of complex samples [18]. The use of 178 
restricted-access materials (RAM) for direct injection of biological samples appears as a good 179 
alternative for selective sample clean-up or fractionation in proteome and peptidome analysis 180 
[19]. Another modern trend in sample preparation for bio-analytical applications is the use of 181 
turbulent-flow chromatography (TFC) that can be even more efficient at removing proteins based 182 
on their size than RAM or SPE [20]. 183 
 The reduction of the analysis time by combining ultra-fast separations and reduced 184 
sample treatments may introduce new analytical challenges during method development. More 185 
matrix related compounds may be introduced into the chromatographic system by reducing 186 
sample treatment, and although higher chromatographic resolution and separation efficiency can 187 
be achieved by UHPLC methods, the likelihood of matrix effects during ionization, such as ion 188 
suppression or ion enhancement, may increase. Additionally, the use of on-line SPE procedures 189 
coupled to UHPLC is not a problem-free approach. Conventional on-line SPE systems are not 190 
usually compatible with UHPLC and a loss on the chromatographic efficiency may be observed 191 
when both methodologies are combined. To solve some of these problems the use of liquid 192 
chromatography coupled to mass spectrometry (LC-MS) or tandem mass spectrometry (LC-193 
MS/MS) is mandatory and for some applications even high resolution mass spectrometry 194 
(HRMS) may be required [21-23]. 195 
 The aim of this review is to discuss the state-of-the-art in fast liquid chromatography 196 
coupled to mass spectrometry and on-line sample preparation techniques for bio-analytical 197 
applications. It should be pointed out that “fast analysis” and “fast chromatography” are terms 198 
currently used without a formal definition. A certain number of compounds analysed per unit 199 
time would be unequivocal analytical parameters. For instance, typical peak widths in routine 200 
UHPLC-MS bio-analyses are 3-10 s [24], while peak widths in the fast/ultrafast LC-MS methods 201 
are generally in the range 1-3 s [25], but they can be narrower than 1 s under well optimized 202 
conditions. However, these parameters are not reported in many cases. In the present review, we 203 
have considered analysis times up to 10 min for both fast chromatography and fast analysis. The 204 
review includes a selection of the most relevant papers recently published (2009-2012) regarding 205 
instrumental and column technology in bio-analysis, particularly UHPLC methods with sub-2 µm 206 
and novel porous shell particle packed columns. Modern sample treatment procedures such as on-207 
line SPE, the use of MIPs and RAM technology, and turbulent-flow chromatography will also be 208 
addressed. 209 
 210 
2. Sample preparation 211 
 212 
2.1. On-line solid phase extraction 213 
 214 
 Laboratory automation and high-throughput analysis have recently become of primary 215 
importance to reduce analysis time, costs and variability derived from sample manipulation. With 216 
the development of fast chromatographic methods able to separate species in a few minutes with 217 
low solvent consumption, it became a priority to shorten conventional sample treatments as well. 218 
In this context, sample preparation using 96-, 384-well or even higher density plate formats is a 219 
well-established technique that has been successfully adopted for semi-automation of off-line 220 
sample procedure in bio-analytical applications [26,27]. 96-well SPE technology and automation 221 
workstations significantly improve the assay sample throughput by reducing both time and labor 222 
required for generating bioanalytical results compared to the conventional off-line SPE methods 223 
[28-31].  224 
 Another powerful alternative to the classical off-line SPE is represented by the on-line 225 
SPE technology. This technique has revolutionized sample preparation, receiving a lot of interest 226 
in recent years because of its ability to dramatically increase assay performance while reducing 227 
total analysis time. Furthermore, recent developments and advancements in on-line SPE aspects 228 
in combination with the sensitivity and selectivity achieved by MS/MS have made possible the 229 
development of faster and precise on-line SPE-LC- and UHPLC-MS/MS methods for both 230 
qualitative and quantitative analysis of several classes of substances in biological matrices. For 231 
instance, it has shown to be very advantageous for the analysis of steroid hormones, insecticides, 232 
antibacterial, perfluorinated compounds, therapeutic peptides, immunosuppressant, 233 
antidepressant or illicit drugs in a wide range of biological fluids such urine, blood, serum, 234 
plasma, saliva, synovial fluid, milk and other tissues (see Table 1, [32-62]). 235 
  The comparison of diverse purification and determination techniques provides evidences 236 
to assess the strengths and limitations of on-line SPE compared to other approaches. For instance, 237 
König et al. [63] developed an on-line SPE LC-MS/MS method for the determination of the 238 
principal psychoactive constituent of cannabis plant and some of its metabolites in human blood 239 
for use in forensic toxicology as an alternative to their pre-existing method based on GC-MS. The 240 
stationary phase of the trapping and analytical columns were hydrophobic. The on-line method, 241 
which was validated, presented limits of detection in the region of 1 µg L
-1
. Furthermore, the on-242 
line SPE permitted overcoming some downsides of the sample treatment stage previous to the 243 
GC-MS analysis such as a laborious sample preparation, long analysis time, and frequent 244 
preventive cleaning of the instrumentation, which is particularly critical with GC-MS. This on-245 
line SPE approach was also used for the analysis of one of the metabolites in human urine [43]. 246 
In this case, no significant matrix effect was observed, excellent intra- and inter-assay precisions 247 
(RSD < 7%) were achieved, with limits of detection in the same range than those observed with 248 
the on-line SPE method developed for blood analysis [63]. Carryover was not observed even 249 
though high levels of the studied compounds were injected [63].  250 
In a study where LLE, protein precipitation, off-line and on-line SPE were assessed for 251 
the analysis of a cephalosporin in plasma, the first two approaches provided low sensitivity and 252 
interferences by endogenous compounds [64]. The off-line clean-up provided the best sensitivity 253 
and selectivity; however the on-line SPE clean-up offered the shorter analysis time as well as a 254 
lower consumption of reagents and still keeping good sensitivity and selectivity. A compromise 255 
between the methods tested gave the optimal results: off-line protein precipitation followed by 256 
on-line SPE method [64], approach carried out in many of the works quoted in Table 1. Examples 257 
of the advantage of using on-line SPE-LC-MS/MS method in terms of reduction of analysis time 258 
were recently reported for the quantification of free catecholamines in urine [65], where it 259 
allowed to perform their determination in 3% of the time initially spent with sample preparation 260 
and chromatographic separation. Another example of short analysis time is the accurate 261 
determination of 3 triazole antifungal drugs in plasma [37] within 3 minutes. To further reduce 262 
run time together with an additional increase in the detection sensitivity, on-line SPE systems 263 
have also been recently coupled to UHPLC using sub-2 μm particle size columns. For instance, 264 
Ismaiel et al. [66] developed a selective UHPLC-MS/MS method for the determination of the 265 
anti-cancer therapeutic peptide ocreotide in human plasma using on-line ion-exchange SPE with 266 
a total run time of 7.5 min and LOQ of 25 pg mL
-1
. Moreover, the on-line removal of 267 
phospholipids using column switching and pre-column back-flushing allowed reducing the 268 
matrix effect to less than 4%. The direct hyphenation of on-line SPE to UHPLC system has also 269 
been reported as a powerful analytical tool for microdosing studies in humans for the clinical 270 
development of drug candidates [34]. Furthermore, this study also compared conventional LC-271 
MS/MS method to UHPLC method; the latter approach leads to 5-fold lower injection volume 272 
and 1.5-fold higher peaks.  273 
On-line SPE methods for bio-analysis provide limited purification in the sense that highly 274 
aqueous solvents are used to wash analytes in the trap column. This rinse step is generally not 275 
enough when hydrolysis or precipitation of macromolecules are required because the system 276 
could get block during the pretreatment [55,61,67]. Precisely, system blockage and ion 277 
suppression are some of the reasons that keep the injection volumes relatively low, typically < 278 
200 µl [61], which play against achieving higher preconcentration factors and sensitivity [45]. To 279 
isolate the analytes from biological matrices, either straightforward or extensive pretreatment 280 
stages have been applied.  Urine samples were just filtered and kept in cool conditions [55]; 281 
saliva was diluted and centrifuged [56]; and serum, plasma and brain microdyalisate samples 282 
were injected directly onto the on-line SPE and proteins rinsed with a solution with high water 283 
content [39,68]. However, most commonly, precipitation of proteins is carried out off-line with 284 
organic solvents [36,37,52,59], acid [38,40,59,61];  and/or centrifugation [56] or even SPE 285 
[52,69], LLE [39] or purification with an immunoaffinity column [57] prior to injection of an 286 
aliquot of the supernatant into the on-line SPE system. Besides, off-line pretreatment is carried 287 
out to increase the lifetime of the costly columns used for SPE [52]. Two consecutive purification 288 
steps with on-line SPE cartridges prior dilution and centrifugation of saliva samples provided 289 
thorough cleaning and allowed to reuse them 15 times with high precision [56]. The effect of the 290 
clean-up on the instrumental sensitivity was assessed by some authors, for instance, 50 injections 291 
of 400 µL of deproteinized plasma into a polymeric SPE cartridge  resulted in a two-fold 292 
reduction of the signal in a MS with off-axis ESI [38]. A novel and promising approach for on-293 
line deproteinization has been carried out with the synthesis of the a polymeric porous monolith 294 
poly(N-isopropylacrylamide-co-ethyleneglycol dimethacrylate), which showed LC-UV 295 
chromatograms with absence of interferences after the direct injection of spiked urine and plasma 296 
[70]. Other approaches to remove macromolecules on-line involving MIPs, RAM and turbulent 297 
flow chromatography will be reviewed in the following sections. Chromatograms obtained with 298 
LC-UV have given an overview on the on-line purification [64,70-74], technique that unlike MS, 299 
also tolerates the presence of phosphate buffers in the mobile phase. When using MS the 300 
purification achieved has been assessed by post-column infusion of the study compound in a 301 
chromatographic run of blank biological sample and observing the reduction of the signal 302 
[56,67,75]; by observing the peak height in absence or presence of matrix [69] or by comparing 303 
the slope of the external calibration curve and standard addition curves [59]. 304 
Most of the compounds analysed, shown in Table 1, were charged low molecular weight 305 
molecules and their determination was carried out with ESI-MS. Ion exchange sorbents could 306 
potentially provide higher selectivity for the extraction of these analytes than reversed phase 307 
sorbents, which would result in cleaner samples and reduced ion suppression. However, the 308 
studies generally opted for sorbents with hydrophobic interaction with the analytes (C4, C8, C18, 309 
polydivinyl-benzene (Hysphere GP resin), N-vinylpyrrolidone–divinylbenzene copolymer 310 
(Waters HLB)). A small number of works chose ion-exchange or mixed-mode ion-exchange as 311 
the purification mechanism. Specifically, functionalized silica with propylcarboxylic acid (CBA) 312 
or with propylsulphonic acid (PRS), and polymer based sorbents such as carboxy-313 
divinylbenzene-N-vinylpyrrolidone co-polymer (Oasis WCX), divinylbenzene-based Bond elute 314 
Plexa PCX or benzenepropanoic acid (Strata X-CW) are among the sorbents most often used in 315 
the works quoted in Table 1 whereas immunosorbents have scarcely been used. 316 
The high versatility and purification potential of on-line methodology has been shown in 317 
the fast and quantitative multicomponent analysis in complex biological samples. As an example, 318 
a simple on-line laboratory set-up was automated for simultaneous determination of forty-two 319 
drugs belonging to different chemical classes in human urine within 11 minutes [42]. The sample 320 
clean-up was performed using a SPE Strata X-CW and the separation was performed by UHPLC-321 
MS/MS. The validation results on linearity, precision, accuracy, matrix and memory effect were 322 
found to be satisfactory, with recovery average greater than 93.8% and LODs/LOQs levels 323 
suitable for confirmation tests.  324 
 325 
2.2. Molecularly imprinted polymers (MIPs) and restricted access materials (RAM) 326 
technology 327 
 328 
 The analysis of compounds in biological fluids is a contest between the analytical 329 
demands (best quality parameters and shortest analysis time) and the complexity of the sample.  330 
 Due to the drawbacks of the commonly used SPE phases, a great effort has been made to 331 
study and develop new sorbents able to increase the overall efficiency of the extraction process 332 
from bio-matrices. These new materials try to accomplish the requirements according to present 333 
needs, such as selectivity towards target analytes, easy manipulation allowing on-line 334 
configurations and higher biocompatibility. Among them, MIPs RAM are currently attracting 335 
much interest.  336 
MIPs, also called synthetic antibodies, are polymeric materials possessing an artificially 337 
generated three-dimensional network with highly specific and selective recognition sites [76]. 338 
These recognition sites are obtained by polymerizing functional and cross-linking monomers 339 
around a template molecule, followed by subsequent removal of the template in order to leave a 340 
cavity with binding sites complementary to the shape, size and functional groups of the target 341 
compound [77]. This technology has grown in popularity over the past few years compared to 342 
other techniques such as conventional SPE or immunoaffinity sorbents because of the advantages 343 
of being at the same time highly selective, cost-effective, and not suffering from storage 344 
limitations and stability problems associated with organic solvents or extreme pH values. An 345 
example of the superior features of MIPs when compared to traditional SPE has been recently 346 
reported for the extraction of an illicit drug such as lysergic acid diethylamide (LSD) from hair 347 
and urine samples [78]. MIP was used for off-line extraction before LC-MS analysis and its 348 
performance compared to that of a conventional C18 SPE. Molecularly imprinted SPE showed 349 
higher recoveries (~83%) than commercially C18 SPE (~65%) with a significant improvement in 350 
analytical sensitivity. Thus, because of the potential benefits of using this technique, MIP–SPE 351 
coupled to LC-MS has been extensively applied for the selective extraction and pre-concentration 352 
of a wide range of analytes, such as benzodiazepines [79], zidovudine and stavudine from human 353 
plasma [80], cocaine and its metabolite benzoylecgonine [81], ketamine and norketamine [82] in 354 
hair samples, as well as testosterone, epitestosterone [83], and 4-(methylnitrosamino)-1-(3-355 
pyridyl)-1-butanol from urine samples [84]. However, even if the use of MIP particles as 356 
selective sorbents for solid-phase extraction (MIP–SPE) is by far the most common application 357 
of MIPs, molecularly imprinted polymers have also been used with satisfactory results as coating 358 
agents for stir bar sorptive extraction (SBSE) and solid-phase microextraction (SPME) fibers, or 359 
as stationary phase for capillary micro-columns. For instance, a high-throughput on-line 360 
microfluidic sample extraction method using capillary micro-columns packed with MIP beads 361 
coupled with tandem mass spectrometry was reported for the analysis of urinary 4-362 
(Methylnitrosamino)-1-(3-pyridyl)-1-butanol [85]. The developed method, which has been 363 
validated according to Food and Drug Administration (FDA) guideline on bio-analytical method 364 
validation [2], has a short run time of 7 min and requires the use of small sample volumes (200 365 
µl), reaching limits of quantitation as low as 20 pg mL
-1
. MIPs, as coating agents for stir bar 366 
sorptive extraction (MISBSE), were also developed for determination of 2-aminothiazoline-4-367 
carboxylic acid (ATCA) as a marker for cyanide exposure in forensic urine analysis [86]. The 368 
performance of this column-less method, based on MISBSE combined with LC-MS/MS, was 369 
demonstrably adequate for the analysis of ATCA at pg µL
-1
 levels without the use of any 370 
derivatization step. Furthermore, MS/MS was used to improve the overall selectivity of the 371 
method and overcome problems associated with matrix interferences due to the possible co-372 
extraction of other urinary acids by the MISBSE procedure. Finally, a somewhat different 373 
approach was recently successfully used for the determination of antibiotics drugs in human 374 
plasma as well as in simulated body fluids [87]. In this study, MIPs were applied as an alternative 375 
for selective SPME coating. MIP-coated fibers for SPME were prepared by using electrochemical 376 
polymerization of pyrrole and linezolid as template molecules. The developed SPME MIP-coated 377 
fibers were then applied to the determination of selected antibiotic drugs such as linezolid, 378 
daptomycin and amoxicillin. The method is shown to be rapid, reproducible and with a detection 379 
limit for linezolid of 29 ng mL
-1
. Furthermore, the selectivity of the SPME MIP-coated fibers for 380 
these antibiotic drugs was assessed by comparing its activity with the non-imprinted polymer 381 
(NIP)-coated fibers. As expected, SPME MIP-coated fibers showed higher binding capacity 382 
compared with NIPs. In summary, MIPs appears as a very useful and promising approach for 383 
sample extraction and clean-up procedure in bio-analytical applications, where a very high degree 384 
of selectivity may be required to reduce analysis time without suffering from problems related to 385 
sensitivity of MS detection such as matrix effects.  RAMs in automated sample preparation 386 
systems on-line coupled with sensitive techniques such as LC-MS/MS or LC-fluorescence have 387 
been an effective strategy to overcome that analytical challenge [88-90]. The use of RAMs 388 
simplifies the purification of low molecular weight substances in bio-fluids by physical and 389 
chemical diffusion barrier. RAMs have a dual surface configuration; the outer surface employs 390 
both size exclusion and hydrophilic shielding to create a non-adsorptive outer surface of the 391 
particles and prevent macromolecules accessing the inner surfaces where smaller molecules can 392 
be adsorbed by hydrophobic interaction.  393 
The RAMs used today are derived from the first sorbents developed in 1985 [91], called 394 
internal surface reversed-phase (ISRP) materials. Alkyl-diol silica materials (ADS) [92] are 395 
among the RAM sorbents most frequently used today and are commercially available. ADS have 396 
a bimodal function based on diol groups in the outer part and hydrophobic extraction phases (C4, 397 
C8 or C18) in the interior. For instance, they have been applied for the analysis of vitamin D and 398 
metabolites from serum [93], mercapturic acids in urine [94,95] or multiresidue analysis of 399 
xenobiotics in urine [96]. But aside from these well-established sorbents, important steps forward 400 
in the development of new RAM sorbents have taken place as it is following described. 401 
The incorporation of restricted access properties to magnetic particles has opened the door 402 
to a new modality of sample preparation supports for bio-analysis. Magnetic porous silica 403 
microspheres were synthetised through polymerization-induced silica/magnetite colloid 404 
aggregation and calcination. The microspheres were subsequently modified with alkyl groups on 405 
the internal surface and diol groups on the external surface [97]. Another magnetic RAM, 406 
schematized in Figure 1, was prepared by functionalizing magnetite nanoparticles with 407 
dodecyltriethoxysilane and non-ionic surfactant (tween). The extraction efficiency was tested for 408 
the analysis of estrogens in urine. Salting out effect was found to increase the extraction 409 
efficiency, pH was not found to be a critical factor for this application and the addition of an 410 
organic modifier reduced their performance [98]. The properties of RAM and MIP materials have 411 
merged in the RAM-MIP grafted silica synthetized by Wenjuan Xu et al. [99], who by a 412 
controlled polymerization technique (see method in [100]) prepared an advanced material 413 
consisting of an internal polymer imprinted with sulfonamides and an hydrophilic external layer 414 
of glycerol monomethacrylate that prevented the adsorption of proteins. This advanced RAM has 415 
been successfully used in the extraction and clean-up of sulphonamides from milk [99]. 416 
Novelties in the uses of RAM to solve bio-analytical problems have also taken place. The 417 
purification of a protein from the family of cytokines, of about 20 KDa, from plasma with RAM 418 
has been carried out despite these sorbents are generally used for retaining low molecular weight 419 
compounds. The RAM used in this case was constituted by silica particles with bonded C18 and 420 
serum albumin [101]. The optimization of the coupling of a RAM (MSpak) with N-421 
vinylacetamide copolymer as stationary phase with a hydrophilic interaction chromatography 422 
(HILIC) column for the analysis of nucleosides in urine, overcoming the compatibility problems 423 
between the solvent required for the elution of the RAM the mobile phase used in the separation, 424 
represented a step forward in this field of sample preparation [102].  425 
Reusing RAM sorbents after being loaded with biological samples which underwent a 426 
minor or no sample treatment [94-96,101,102] proves the efficiency of the technique and shows 427 
its superiority to the single use of SPE cartridges. However, despite the advantageous features of 428 
RAMs, these materials still have limitations. The elution of the analytes from the RAM to the 429 
analytical column is a key step in the purification process; the sorbent could still contain residues 430 
of macromolecules at this point if the washing step has not been fully effective. To avoid the 431 
precipitation of residual macromolecules in the RAM, the amount of organic solvents in the 432 
transference is kept low, usually below 15%, but a disadvantage of the weak eluotropic strength 433 
of the transfer solution is that residual amounts of the analytes can remain in the sorbent and 434 
cause false positives. Carryover may be likely to be happen when injecting a hydrophobic analyte 435 
in a reversed phase RAM. For instance, carryover of bosentan and metabolites, which are 436 
compounds with 4 aromatic cycles, was assessed to happen at about 0.2% of the last injected 437 
sample [103]. The assessment of carryover can be carried out directly with the analysis of blanks 438 
[96,101,103]  or indirectly with the assessment of  the recovery through the RAM [102], recovery 439 
of the whole analysis including sample treatment, separation and detection [101] or analysis of 440 
reference materials [93]. 441 
 442 
2.3. Turbulent flow chromatography 443 
 444 
 Turbulent flow chromatography is widely used in applications were plasma or similar 445 
fluids are to be analyzed. This technique allows the direct injection of a liquid sample onto a 446 
narrow diameter column (0.5 or 1.0 mm) packed with large particles (30-60 µm) at a high flow 447 
rate (higher than 1 mL min
-1
). Under turbulent flow conditions, there is improved mass transfer 448 
across the bulk mobile phase which allows improving the radial distribution of the analytes. 449 
However, under these conditions, a laminar zone where diffusional forces still dominate the mass 450 
transfer process still exists around the stationary phase [104]. Molecules with low molecular 451 
weight diffuse faster than molecules with high molecular weight, forcing large molecules to 452 
quickly flow to waste while retaining the small ones. The retained compounds are then back-453 
flushed and focused on the analytical column for chromatographic separation, like in an on-line 454 
extraction with RAM. The first application of TFC-MS for the direct injection of plasma was 455 
described in 1997 by Ayrton et al. [105]. Many more studies have been reported in successive 456 
years applied to various matrices covering from biological (Table 2, [104,106-118]) to 457 
environmental and food samples. For example, the successful analysis of immunosuppressants 458 
and antibiotics from low volume samples such as ocular fluid (tears) and whole blood has been 459 
reported [106,119,120]. Besides, this technology has been applied to the analysis of more 460 
complex matrices such as hemodialysates [121], edible animal tissues [122] and food samples 461 
such as honey [123] and milk [124]. The major advantage of TFC in comparison to other 462 
extraction techniques is the reduction of time consuming preparation steps while similar LOQ, 463 
dynamic range, accuracy and precision can be obtained.  The main drawback of this technique is 464 
probably the low concentration capacity achieved although this can be compensated by the use of 465 
capillary LC leading to the reduction of the amount of sample volume injected [125].  In addition, 466 
this technique is clearly limited in terms of chromatographic resolution. Therefore, it is common 467 
to couple turbulent flow columns to a more conventional analytical column by means of column 468 
switching systems. TFC is considered to be similar to SPE followed by liquid chromatography 469 
although the extraction in TFC is size-exclusion based, therefore it is mainly applied when there 470 
is an interest to separate small analyte molecules from larger matrix molecules [125]; the larger 471 
molecules, such as proteins, go directly to waste and the smaller molecules are adsorbed to the 472 
retentive stationary phase of the turbulent flow column. Nevertheless, TFC seems to be more 473 
efficient at removing proteins than RAM or SPE [126]. In general its simplicity, versatility and 474 
automation possibilities are well described in the literature as it dramatically increases the speed 475 
of the analysis while maintaining acceptable levels of recovery, efficiency and robustness. The 476 
analysis time can vary between 2-9 minutes depending on the number of compounds and the 477 
number of channels used (multiplexing). Mueller et al. described a reduction of 50% on the 478 
analysis of sirolimus and everolimus by using TFC, nevertheless the analysis time reported (5.75 479 
minutes) is longer in comparison to other on-line methods [106]. The authors adopted a slightly 480 
longer analysis time in a way to have better robustness, no carryover and extended column 481 
lifetime (>600 injections) provided by extending cleaning and equilibration times. On the other 482 
hand, real screening methods including a large number of analytes have also been reported where 483 
the analysis time can be extended to up 32 minutes [107]. In this case, more than 400 compounds 484 
are included in the acquisition list. Off-line handling of the sample is often limited to 485 
centrifugation, for removal of particulates, dilution with internal standard and protein 486 
precipitation (PPT) to remove endogenous binding proteins [109]. The latter helps preventing 487 
column clogging. 488 
 Mueller et al. [107] reported a comprehensive toxicological MS
n
 screening method for the 489 
analysis of serum and heparinised plasma. This methodology targeted 453 compounds and the 490 
results were cross-checked with urine samples to test the performance of the method under 491 
realistic clinical conditions as well as to compare the information gathered using different 492 
matrices. Pérez et al. [108] applied the same principles for bioaccumulation studies of 493 
perfluorinated compounds in human hair and urine. Similar results were obtained between 494 
radioimmunoassay and TFC by Bunch et al. [109] in the analysis of 25-hydroxyvitamin D2 and 495 
D3 in serum.  496 
 The sample preparation technique used has clear effects on the composition of the 497 
purified extract. In the case of metabonomic studies, an automated sample preparation 498 
methodology in which the sample can be injected directly into the system is appealing. 499 
Michopoulos et al. [104] reported that even though the use of TFC in metabonomic studies is 500 
feasible, different profiles were obtained when comparing TFC and protein precipitation. This 501 
was attributed to the greater amount of phospholipids in the protein-precipitated samples, due to 502 
fact that TFC would not affect the binding of such compounds to proteins; they would pass 503 
through the first column without being retained [104]. 504 
 The robustness of sample preparation techniques in quantitative assays is crucial. 505 
Methods using PPT are simple and cheap but produce relatively dirty extracts which may reduce 506 
the lifetime of the chromatographic column, extend the cleaning/maintenance of the mass 507 
spectrometer or result in matrix effects [127]. LLE and SPE are effective in terms of producing 508 
clean extracts and reducing matrix effect but are alsolaborious and difficult to automate.  509 
 TFC can also be used for analytical support of in vivo pharmacokinetics and in vitro drug 510 
metabolism studies [113,128]. Verdirame et al. [113] reported the advantage of TFC 511 
methodologies in terms of sensitivity and throughput in comparison to conventional procedures. 512 
In this case, a set up consisting of two parallel turbulent flow and two analytical columns 513 
operating independently was used. This configuration allowed a 4-fold improvement in terms of 514 
throughput.  515 
 Summarizing, the optimization of the different on-line extraction steps is crucial, as 516 
parameters like mobile phase composition, flow rates and extraction time windows will affect 517 
recovery and extraction efficiency. In general, TFC provides simplicity, automation, robustness, 518 
versatility and high-throughput in bio-analysis.  519 
 520 
3. Trends in chromatography approaches 521 
 522 
3.1. Ultrahigh pressure liquid chromatography 523 
 524 
 Fast chromatography has become a reality in laboratories that require analyzing hundreds 525 
of samples per day or those needing short turnaround times. The development of columns packed 526 
with sub-2 µm particles and the commercialization of LC systems capable of withstanding 527 
pressures as high as 1000 bar lead to a significant increase in the analysis throughput. By using 528 
UHPLC, the results of a sample batch can be reported in a few hours rather than a few days as it 529 
is needed, for instance, in doping control laboratories. Thus, the demand of high sample 530 
throughput in short time frames have given rise to high efficiency and fast liquid 531 
chromatographic separations in several fields, including bio-analysis, using mainly reversed-532 
phase columns packed with sub-2 µm particles. Moreover, this column technology for UHPLC 533 
emerged as a powerful approach particularly because of the ability to transfer existing HPLC 534 
conditions directly [129]. 535 
 In general, fast chromatographic separations can be achieved either by increasing the 536 
mobile phase flow-rate, by decreasing the column length or by reducing the column particle 537 
diameter. Based on the van Deemter theory [130], then on Giddings [131], and later on Knox 538 
[132] and further interpretations, the efficiency, expressed as the height equivalent to a theoretical 539 
plate (HETP, H), can be described as: 540 
 541 
H = A + B/u + Cu = 2λdp + 2γDM / u + f(k)dp
2
u / DM  542 
 543 
where u is the linear velocity of the mobile phase, and A, B, and C are constants related to Eddy 544 
diffusion, longitudinal diffusion and mass transfer in mobile and stationary phase, respectively, 545 
dp is the particle diameter of the column packing material, DM is the analyte diffusion coefficient, 546 
λ is the structure factor of the packing material, γ is a constant termed tortuosity or obstruction 547 
factor and k is the retention factor for a given analyte [130]. So basically, HETP depends on three 548 
terms, which are the brand broadening due to Eddy diffusion coefficient (A-term), longitudinal 549 
diffusion coefficient (B-term) and the resistance to mass transfer coefficient between the mobile 550 
and stationary phases (C-term). It is often assumed that A-term does not depend on temperature 551 
and it is directly proportional to dp, while B- and C-terms are both temperature dependent, the B-552 
term being directly proportional to DM while the C-term is inversely proportional to DM but 553 
directly proportional to the square of dp. So, as lower is the particle diameter of the column 554 
packing material higher will be the column efficiency (lower HETP), and high throughput 555 
separations will be achieved. The use of small particles will induce a considerable increase in 556 
pressure drop, but this inconvenience has been resolved with the availability of new ultra-high 557 
pressure resistant LC systems allowing to profit fully from the advantages in using sub-2 µm 558 
particle packed columns.  559 
 The narrow peaks that will be produced by fast UHPLC separations will require detection 560 
systems with a small detection volume and fast acquisition rates in order to keep the high 561 
efficiency gained in the separation. Most of the commercial UHPLC instruments available are 562 
equipped with modified UV detectors, with flow cell volumes much lower than those for 563 
conventional HPLC, in order to ensure the optimal peak capture. However, due the complexity of 564 
sample matrices such as biological samples, UHPLC couple to mass spectrometry has become 565 
the method of choice in bio-analytical applications in order to guarantee the confirmation of 566 
target compounds. Moreover, because UHPLC enhances chromatographic resolution overall, co-567 
elution is reduced, and that, in turn, leads to a decrease of ion suppression, improving MS 568 
sensitivity and reliability. However, since UHPLC greatly enhances separation throughput and 569 
resolution, base peaks as narrow as 1 s (or even lower) can be obtained creating practical issues 570 
for bio-analytical applications. MS instruments are required to work at low dwell times and low 571 
inter-channel and inter-scan delays in order to achieve a sufficient amount of data points (e.g., > 572 
15 points per peak) for UHPLC methods to ensure reliable quantitation [24].   573 
 Several recent applications of UHPLC-MS methods in bio-analysis using sub-2 µm 574 
particle size packed columns are summarized in Table 3 [42,58,59,66,133-157]. As can be seen, 575 
most of the UHPLC applications using columns packed with sub-2 µm particles are focused in 576 
the analysis of mainly plasma (or blood related matrices) [58,59,66,133-144,150,151,153,155-577 
157] and urine [42,138,139,142,146-150] matrices, although applications in other biological 578 
samples such as several tissues [153,154], tumor tissues [152,153], faeces [150], human seminal 579 
plasma [145], and saliva [142] have also been reported. For instance, Baumgarten et al. [152] 580 
developed an UHPLC-MS/MS method using a C18 column packed with 1.6 µm particles for the 581 
rapid confirmation of doxorubicin drug delivery in liver cancer tissue after a transcatheter arterial 582 
chemoembolization treatment used for palliative therapy. The method allowed the separation of 583 
doxorubicin and daunorubicin within 1 min and helped in the better understanding of the factors 584 
affecting the delivery and dispersion of doxorubicin within treated tumors during these 585 
treatments. McWhinney et al. [142] developed an UHPLC-MS/MS method for the laboratory 586 
routine analysis of glucocorticoid hormones in several matrices such as plasma, plasma 587 
ultrafiltrate, urine and saliva. As an example, Figure 2 shows the chromatographic separation of 588 
cortisol, cortisone, 11-deoxycortisol, prednisolone and dexamethasone hormones (Figure 2a) as 589 
well as the chromatograms obtained after application of the proposed UHPLC-MS/MS method to 590 
the analysis of several matrices (Figures 2b-2f). Chromatographic separation of all 591 
glucocorticoids in less than 2.5 min was achieved showing limits of quantitation in the range of 1 592 
to 5 nmol L
-1
 (depending on the sample matrix) and with intra-assay and inter-assay precisions 593 
with RSD values lower than 5 and 10%, respectively, for all compounds in all matrices.  594 
 Most of the applications are based on reversed-phase separation using the Acquity UPLC 595 
BEH C18 column of 1.7 µm particle size with different columns lengths (30, 50 or 100 mm), but 596 
other C18 reversed-phase columns such as Zorbax Eclipse XDB-C18 (1.8 µm particle size) 597 
[42,59,136,139,150], Shimadzu Shim-pack ODS (1.6 µm particle size) [152] or Hypersil Gold 598 
C18 (1.9 µm particle size) [58,144,148,151,157] have also been used. Although not strictly sub-2 599 
µm particle size columns, some bio-analytical UHPLC-MS applications can be found using 600 
columns with slightly higher totally porous particle sizes. As an example, Tuffal et al. [140] 601 
reported the use of a Shimadzu Shim-pack XR-ODS II column of 2.2 µm particle size for the 602 
UHPLC-MS separation of clopidogrel active metabolite isomers in plasma in less than 7 min. 603 
Other stationary phases have also been described for UHPLC-MS bio-analytical applications. For 604 
instance, the use of a high strength silica (HSS) column (Acquity UPLC HSS T3, 1.8 µm particle 605 
size) was reported by Vanden Bussche et al. [149] for the analysis of eight thyreostats in urine, 606 
without any derivatisation, in less than 6.5 min. While Jiménez Giron et al. [146] used a C8 607 
reversed-phase column (Zorbax SB-C8, 1.8 µm particle size) for the UHPLC-High resolution 608 
Orbitrap MS screening analysis of diuretic and stimulant compounds in urine for doping control. 609 
By screening in full scan MS with scan-to-scan polarity switching more than 120 target analytes 610 
could be detected in less than 8 min. 611 
 Regarding MS detection, triple quadrupole analyzers are instruments of choice for 612 
UHPLC-MS bio-analytical applications as can be seen in Table 3. Other MS and HRMS 613 
instruments have also been used for some bio-analytical applications, which will be discussed in 614 
further detail in section 4. 615 
 616 
3.2. Fused-core particle packed columns 617 
 618 
 The recent commercialization of fused-core (also known as porous shell) particle 619 
technology presents a new option for HPLC bio-analytical applications in order to achieve fast 620 
chromatographic and high efficiency separations. Today, columns packed with porous shell 621 
particles consisting of silica particles of a 1.7 µm fused core and 0.5 µm layer of porous silica 622 
coating, creating a total particle diameter of 2.7 µm, are available under the brand name HALO 623 
(Advance Materials Technology) or Ascentis (Sigma-Aldrich). Other particle diameter sizes are 624 
also available such as in the case of Kinetex (Phenomenex) columns with a 1.9 µm fused core 625 
and 0.35 µm layer of porous silica coating, obtaining 2.6 µm particles and Accucore (Thermo 626 
Fisher Scientific) columns with also a total particle diameter of 2.6 µm. This fused-core column 627 
technology, with a solid silica inner core surrounded by a porous silica shell has a shortened 628 
diffusion path which allows rapid mass transfer and thus reduced axial dispersion and peak 629 
broadening [158]. The reduction in axial diffusion makes possible working at higher flow- 630 
without losing chromatographic performance [159]. So, fused-core silica particles offer the 631 
possibility to improve chromatographic column efficiency over fully porous particles, and exhibit 632 
efficiencies that are comparable to sub-2 µm porous particles, but with lower backpressures. For 633 
instance, Figure 3 shows the chromatographic separation of bromo-guanosine, labetalol, reserpine 634 
and a selected drug compound obtained with two conventional particle size columns (Luna 635 
C18(2) HST 2.5 µm and Luna PFP 3 µm), a sub-2 µm particle size column (Acquity BEH C18 636 
1.7 µm) and a fused-core column (Ascentis Espress C18 2.7 µm) [160]. The fused-core column 637 
showed similar peak widths than the other columns (similar column efficiency) at approximately 638 
75% of the maximum specified backpressure for this column, even after more than 1500 639 
injections of protein precipitated plasma extracts. It should be noted that the most popular 640 
UHPLC stationary phase material, Acquity BEH C18 1.7 µm column, operates at high 641 
backpressure (>700 bars) even with the column oven set at 65 
o
C (combined with an efficient 642 
mobile phase pre-heating device in-line prior to the UHPLC column). Higher pressures were 643 
obtained when the column oven temperature was set at 40 
o
C, leading to concern regarding the 644 
robustness of the system for application in the successful conduct of thousands of analyses of 645 
extracted plasma samples. 646 
The use of porous shell column technology is a relatively recent trend in chromatographic 647 
separations and only a few papers about bio-analytical applications are described in the literature, 648 
and some of the most recent ones have been included in Table 4 [160-165]. As can be seen, all 649 
the applications are dealing with C18 reversed-phase separations. As in the case of columns 650 
packed with sub-2 µm particles, triple quadrupole instruments are usually selected for UHPLC-651 
MS applications. For instance, Song et al. [165] proposed an UHPLC-MS/MS method using a 2.7 652 
µm fused-core column and a triple quadrupole instrument for the analysis of imipramine and 653 
desipramine antidepressants in protein precipitated rat plasma samples, and a separation within 654 
2.5 min was achieved at a flow rate of 0.4 mL min
-1
, with acceptable intra-run precisions and 655 
accuracies (within 14.4 and 14.7% at the LOQ level for both analytes). However, other MS 656 
instruments such as quadrupole linear ion traps for the analysis of oseltamivir and 657 
oseltamivircarboxylate in dried blood spots [163], or even high resolution mass spectrometry 658 
using a TOF MS instrument for the UHPLC-MS analysis of isoliquiritigenin metabolites in urine 659 
[162] or a linear ion trap-Orbitrap HRMS instrument for the analysis of glutathione-trapped 660 
reactive metabolites in plasma [161] have also been reported.  661 
 662 
4. Mass spectrometry in bio-analysis 663 
 664 
LC-MS has proven to be a powerful technique in bio-analysis. ESI and atmospheric 665 
pressure chemical ionization (APCI) are the most common ionization sources used in LC-MS. 666 
Nevertheless, ESI operating in both negative and positive modes is in general the most selected 667 
ionization source in bio-analytical science (Table 3 and 4). However, many studies have reported 668 
difficulties with reproducibility and accuracy when analyzing small quantities of analytes in 669 
complex samples such as biological fluids. Because of the specificity of the MS methods, 670 
analysis times in LC–MS assays are often reduced significantly by researchers, due to the 671 
misconception that chromatographic separation and sample preparation can be minimized or even 672 
eliminated. However, LC–MS by itself does not guarantee selectivity. Disregarding sample 673 
clean-up, especially when complex matrices are involved, will lead to poor performance. Thus, 674 
careful consideration must be given to the evaluation and the elimination matrix effects when 675 
developing any assay. Ion suppression is one the major problems in LC-MS with atmospheric 676 
pressure ionization (API) sources, especially with ESI. Ion suppression occurs due to the 677 
competition among several ions during ion evaporation [166]. Nowadays, as it is reported in this 678 
review, fast liquid chromatography and fast sample analysis are commonly used to reduce the 679 
analysis time and determine the maximum number of compounds in the same run. However, 680 
important matrix effects can be present and its evaluation is necessary to obtain accurate 681 
quantitation results. Generally, in order to reduce matrix effects, one strategy can be to improve 682 
the sample preparation procedure which is in conflict with the fast and non-selective sample 683 
treatment procedures that are demanded. Recent breakthroughs in sample clean-up have been 684 
achieved to exploit on-line SPE and TFC with column switching systems, where matrix 685 
components are diverted to waste before the elution step, hence the amount of undesirable 686 
compounds reaching the LC-MS system is reduced. Another way to reduce the matrix effect is to 687 
optimize the chromatographic separation and increase the chromatographic resolution. In this 688 
way, and as it was commented in the section 3.1 and 3.2 the use of sub-2 µm particle size 689 
columns and porous shell columns is increasing. Nevertheless, important matrix effects can still 690 
be observed and the use of alternative ionization sources less sensitive to matrix effects such as 691 
APCI and atmospheric pressure photoionization (APPI) is proposed. For instance, Mueller et al. 692 
[106] developed a TFC-LC-MS/MS method using APCI as ionization source for the analysis of 693 
sirolimus and its derivative everolimus, two immunosuppressive agents, in whole blood in order 694 
to reduce the matrix effects observed when ESI was used. APCI ionization source has been also 695 
used for the multi-screening of drugs and metabolites in serum and plasma [107,114], as well as 696 
for the analysis of vitamins [109] and tyrosinekinase inhibitors [111]. On the other hand, some 697 
results indicate that APPI is less susceptible to ion suppression and salt-buffer effects than ESI 698 
and APCI [167]. For instance, Borges et al. [48] developed a LC-APPI-MS/MS method for the 699 
analysis of ethinylestradiol in human plasma. In this study the use of APPI provided better 700 
sensitivity than ESI and in addition no significant matrix effects were observed making possible 701 
the analysis of ethinylestradiol at low concentration levels. On the other hand, this ionization 702 
technique has been successfully used for the analysis of a broad spectrum of non-polar lipids 703 
such as steroids, (glycol-)sphingolipids, and phytosterols [168]. However, until now there are 704 
only few publications regarding the use of APPI in bio-analysis and much work needs to be done 705 
to evaluate its potential in this area. 706 
Triple quadrupole instruments operating in selected reaction monitoring (SRM) mode are 707 
the most common analyzers used in bio-analysis (Table 3 and 4). As a compromise between 708 
sensitivity, acceptable chromatographic peak shape, and the confirmation purposes established by 709 
2002/657/EC directive [3] two SRM transitions are currently monitored. However, in some cases 710 
the use of only two transitions could result in false-positive or false-negative confirmations when 711 
the compound co-elutes with an interfering matrix compound with ions in the MS/MS spectrum 712 
matching with those of the target analyte [169-171]. In these cases, false-positive results can be 713 
prevented with by further confirmatory analysis, e.g. the use of a third transition or an orthogonal 714 
criterion like exact mass measurements. On the other hand, despite its high selectivity and 715 
sensitivity the use of SRM acquisition mode in QqQ instruments is limited by the cycle time 716 
when dealing with hundreds of compounds, and a significant drawback to this type of analyzers 717 
is that only those molecules that have been targeted are detected (missing non-target compounds 718 
or even target metabolites). For these reasons, nowadays to solve the problems related to both the 719 
cycle time and the target screening method, liquid chromatography coupled to high resolution 720 
mass spectrometry (LC-HRMS) is being implemented in bio-analysis. Time-of-flight (TOF) and 721 
Orbitrap based technologies are currently the most common analyzers used in LC-HRMS. For 722 
instance Fung et al. [172] proposed a LC-HRMS method using a quadrupole-time-of-flight (Q-723 
TOF) analyzer for the analysis of prednisone and prednisolone in human plasma operating at a 724 
mass resolving power of 10,000 and obtaining mass errors below 6 ppm. On the other hand, 725 
Jiménez Girón et al. [146] reported a new screening method based on UHPLC-HRMS using 726 
polarity switching for the analysis of 122 targeted analytes in urine by direct analysis. In this 727 
work the use of polarity switching acquisition mode in combination with HRMS allowed the 728 
possibility to obtain two diagnostic ions. This strategy was used to confirm some diuretics 729 
compounds that exhibit high sensitivity in negative mode but were also detectable in positive 730 
mode. The use of high resolution mass spectrometry is also especially useful in metabolomics 731 
studies where full scan MS spectra and accurate mass measurements are acquired for 732 
identification purposes [173]. The use of ultra-high resolution mass spectrometry, operating at 733 
mass resolving power higher than 30,000 FWHM is especially important in lipidomics studies 734 
due to the complexity of this family of compounds. Taking advantage of the ultra-high resolution 735 
provided by an Orbitrap analyser isobaric phosphatidylethanolamines (PE) ether species with 7 736 
double bonds (which are common in several model organisms, such as C. elegans) could be 737 
differentiated from the PE ester species with two saturated fatty acid moieties having a mass 738 
difference of 0.0575 Da (Figure 4, [174]). However, in this case operating at ultra high resolution 739 
mass spectrometry has compromised the scan speed and therefore the coupling to fast LC 740 
separation. 741 
However, in some cases the unequivocal identification of target and target-related 742 
compounds requires combining the information provided by HRMS and MS/MSexperiments. 743 
Moreover, accurate mass measurements and elemental composition assignment are essential for 744 
the characterization of small molecules. For instance, the accurate mass measurements of the 745 
product ions generated in MS
n
 experiments facilitate the elucidation of unknown compounds 746 
structures, making attractive the use of hybrid mass spectrometers such as Q-TOF, ion-trap - 747 
time-of-flight, linear ion-trap quadrupole – Orbitrap (LTQ-Orbitrap) and quadrupole-Orbitrap (Q-748 
Exactive). In this way, a new concept in tandem mass spectrometry, “all ion fragmentation” 749 
(AIF) experiments, have been recently introduced. This acquisition mode enables the 750 
combination of the fragmentation of all generated ions entering into the collision cell with the full 751 
scan MS data, allowing retrospective data evaluation for unknown substances in any untargeted 752 
approach, and consequently providing an extra confirmation strategy. AIF acquisition mode has 753 
become highly important in some bio-analytical applications such as in doping control. For 754 
instance, Thomas et al. [157] developed a LC-HRMS(/MS) method for the analysis of some 755 
prohibited drugs in dried blood spots for doping control with AIF acquisition mode. This strategy 756 
was also followed by Zhu et al. [161] in the screening of glutathione-trapped metabolites in 757 
human plasma where AIF, non-selective in-source collision-induced dissociation (SCID) 758 
fragmentation and HRMS were used. Study in which the putative metabolites could be confirmed 759 
and their structures elucidated with the corresponding high resolution full scan and high 760 
resolution MS/MS data acquired using a LTQ-Orbitrap velos instrument.  761 
 762 
Conclusions and future perspectives 763 
  764 
 Fast or ultra-fast separation methods appear as a good tool to satisfy the necessity of 765 
reducing the total analysis time in bio-analysis where a high number and variety of samples are 766 
being analyzed, and in areas where results must be reported promptly. The state-of-the-art of fast 767 
LC-MS for bio-analytical applications have been discussed in this review. Nowadays, UHPLC 768 
technology is the most convenient approach to achieve modern, high throughput, efficient, 769 
economic and fast LC separations for bio-analytical applications using sub-2µm particle size 770 
packed columns. Although different stationary phases i.e. reversed phase, hydrophilic interaction 771 
liquid chromatography (HILIC), fluorinated columns, etc. are available in sub-2µm particle size 772 
columns, most of the bio-analytical applications are still focused mainly in C18 or C8 reversed-773 
phase columns (Table 3). The use of HILIC is becoming very popular for bio-analytical 774 
applications allowing better separation of highly polar compounds than with reversed-phase 775 
chromatography and it will become a complementary tool to explore in the near future for 776 
UHPLC bio-analytical applications. Although separation with columns packed with sub-2µm 777 
particles requires special instrumentation because of the high pressures achieved, instruments 778 
adapted to operate at these pressures are commercially available. However, this drawback can 779 
also be compensated with the use of porous shell columns, which can be employed in any HPLC 780 
or UHPLC instrument because the fused-core particle design allows to considerably reducing 781 
column backpressure but keeping similar column efficiency than what is achieved in sub-2µm 782 
particle size columns. Columns packed with porous shell particles seems to be a more 783 
advantageous approach to easily achieve fast LC separations even when using conventional LC 784 
instrumentation, and it will also become a field to explore in the next years for bio-analytical 785 
applications as an alternative to sub-2µm particle size columns.   786 
 Despite the important advances in fast liquid chromatography able to separate species in a 787 
few minutes with low solvent consumption, sample extraction and clean-up treatments must be 788 
carefully developed to reduce total analysis time. The most recently introduced sample treatment 789 
automated methodologies in bio-analytical applications have also been addressed in this review, 790 
such as on-line SPE, TFC, MIP and RAM based methods.It should be pointed out that sample 791 
preparation techniques must be chosen and optimized on the basis of the method purpose and 792 
take into consideration the chromatographic separation that will be used. In this context, recent 793 
developments in on-line SPE aspects in combination with the sensitivity and selectivity achieved 794 
by MS/MS have made possible the development of faster and precise on-line SPE-LC- and 795 
UHPLC-MS/MS methods for both qualitative and quantitative analysis of heterogeneous 796 
substances in biological matrices.  797 
 TFC appears as a very useful approach for sample treatment in bio-analytical applications 798 
where plasma or similar fluids need to be analyzed by removing proteins based on their size 799 
better than restricted access materials or SPE procedures. For these reasons, TFC is one of the 800 
modern approaches in sample treatment procedures that is becoming more popular and a number 801 
of applications are expected to be available in the future beyond the bio-analytical field.  802 
 MIPs and RAM have attracted much interest in the last years (Table 1). The use of MIP is 803 
a very useful approach for some bio-analytical applications because it makes possible to achieve 804 
a selective preconcentration ot the target analytes. One of the main advantages of MIPs is the 805 
possibility to prepare selective sorbents pre-determined for a particular substance or a group of 806 
structural analogs, which will become very useful for some specific applications. On-line RAM 807 
(together with TFC) are solvent-less techniques and, although using mobile phase for sample 808 
elution, are among the most environmentally friendly sample treatment procedures. And although 809 
some drawbacks exits when using RAM such as the risk of carryover when the sample contains 810 
hydrophobic species and the method involves reversed-phase RAM and transfer solutionwith low 811 
elutropic strength, advances are taking place in the development of new RAM sorbents. For 812 
instance, the incorporation of restricted access properties to magnetic particles are providing 813 
supports for new and relevant bio-analytical applications.  814 
 Regarding mass spectrometry, the use of triple quadrupole instruments monitoring two 815 
SRM transitions is the most common approach used for bio-analytical applications. Nevertheless, 816 
in several cases the use of only two transitions resulted in false-positive or false-negative 817 
confirmations. Moreover, one of the major drawbacks in bio-analysis when using QqQ analyzers 818 
is that only targeted molecules are being detected, missing important information for some bio-819 
analytical applications. Nowadays, HRMS, either using TOF or Orbitrap analyzers, is being 820 
implemented in bio-analytical analysis to solve these problems. The possibility of working at 821 
high resolving power together with accurate mass measurements makes these instruments ideal to 822 
facilitate identification of unknown compounds which is essential for some bio-analytical 823 
applications. In this way, Orbitrap instruments working in AIF modewill become a powerful tool 824 
for bio-analytical applications in the future.  825 
  Comprehensive analysis and testing is needed to evaluate these methodologies applied 826 
into bio-analytical applications. It is necessary that all steps in analytical method development, 827 
sample treatment (extraction and clean-up), chromatographic separation and detection, are 828 
developed and optimized in alignment, focusing in the reduction of the total analysis time in 829 
order to achieve fast methods but without compromising the reliability and quality of the  830 
analytical results, especially in a field with direct implications for human health such as bio-831 
analysis.  832 
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Figure 1. Schematic presentation of a synthetic route of surfactant-coated C12-MNPs. Reproduced 1151 
from ref. [98], with permission of Elsevier. 1152 
 1153 
Figure 2. Representative UHPLC-MS/MS chromatogram of glucocorticoids. (a) Standard with 1154 
cortisol, cortisone, 11-deoxycortisol, prednisolone and  dexamethasone. (b) Dilute plasma 1155 
ultrafiltrate with cortisol. (c) Saliva sample with cortisol and cortisone. (d) Plasma ultrafiltrate 1156 
with  cortisol. (e) Plasma sample from a patient collected at 09:00 after administration of 1 mg 1157 
dexamethasone at 23:00 the previous evening. (f) Urine from a patient on prednisolone treatment. 1158 
Reproduced from Ref. [142], with permission of Elsevier. 1159 
 1160 
Figure 3. Gradient UHPLC-MS/MS chromatograms of the (i) bromo-guanosine, (ii) labetalol, 1161 
(iii) reserpine and (iv) drug compound SB243213A test mix on several possible columns for 1162 
generic gradient UHPLC-MS bio-analysis. All columns were of 50 mm x 2.1 mm I.D.: (a) Luna 1163 
HST C18(2) 2.5 µm, (b) Luna PFP 3 µm, (c) Acquity BEH C18 1.7 µm (n=4 chromatograms 1164 
overlaid) and (d) Ascentis Express C18 2.7 µm (n=4 chromatograms overlaid). Reproduced from 1165 
Ref. [160], with permission of Elsevier. 1166 
 1167 
Figure 4. LTQ Orbitrap analysis of isobaric species PE 18:0/18:0 and PE O-16:1p/22:6. The time 1168 
needed for performing one scan at given resolution settings is highlighted in boxes. Reproduced 1169 
from Ref. [174], with permission of Thermo Scientific. 1170 
Table 1. Use of on-line SPE procedures in bio-analytical applications.  
Target compounds Sample SPE Stationary phase Elution Solvents Analytical technique Analytical features Reference 
Pharmaceuticals and drugs 
FTY720, FTY720-P Blood HySphere C18 HD 7mm Dimethylhexylamine solution (A) and 
acetonitrile/isopropanol 
(80:20, v/v) (B) 
LC-ESI-MS/MS LOQs > 0.08 ng mL-1 [32] 
Sirolimus 
and everolimus 
Blood Zorbax Extend-C18 
(2.1 mm×12.5 mm, 5 µm) 
Methanol (A) and water (B) both containing 
0.1% formic acid 
in 2 mmol L−1 ammonium formate 
LC-ESI-MS/MS LODs > 0.1 ng mL-1 
LOQs > 0.2 ng mL-1 
[33] 
Pharmaceutical compound 
and its metabolites 
Plasma Gemini C18  
(2mm×10mm, 5 µm) 
5mM ammonium formate and  0.2% formic 
acid in water/acetonitrile (80:20, v/v)  
UHPLC-ESI-MS/MS LOQs > 5 ng mL-1 [34] 
Fluoxetine Plasma Kromasil C18 
( 1mm×5mm, 5 µm) 
Acetonitrile and  0.05 mol L−1 ammonium 
formate buffer (25:75, v/v) 
Capillary LC-ESI-
TOF-MS 
LODs > 3 ng mL-1 
LOQs > 5 ng mL-1 
[35] 
Amlodipine Plasma HySphere C8 EC-SE (2 mm× 10) 
 
After treatment with acetonitrile , 0.1% formic 
acid in water (A) and methanol (B). 
LC-ESI-MS/MS LOQ 0.10 ng mL-1 [36] 
Fluconazole, itraconazole, 
posaconazole and 
voriconazole (antifungal 
drugs) 
Plasma Waters Oasis HLB column 
 (2.1×20 mm, 25 μm) 
Acetonitrile/water 80/20 (A), 2 mM 
ammonium formiate (B)  
LC-MS/MS LOD 2–10 ng mL-1 [37] 
Pharmaceuticals  Plasma Oasis® HLB cartridge column 
(2cmL×2.1mmID, 25µm) 
0.1% ammonium acetate (A) and 0.1% 
methylamine in 
methanol (B) 
LC-MS/MS LOD 19-100 pg mL-1 [38] 
Pharmaceutical 
Remoxipride (dopamine 
D2 receptor antagonist) 
Plasma and Brain 
homogenate and 
dialysate 
Oasis®weak cationic 
exchange (WCX) cartridges 
Acetonitrile with 16mM acetic acid (7:3, v/v, 
0.1% TFA, pH 2). 
LC-MS/MS LOQ 0.5 ng mL-1 
(plasma) 
 
LOQ 0.25-1.8 ng mL-1 
( Brain homogenate 
and dialysate) 
[39] 
Indacaterol Serum Oasis MCX,  
(1mm× 
10 mm 
After acidification, centrifugation, 0.03% 
ammonia (A) and methanol (B). Vinj 150 µl. 
 
LC-ESI-MS/MS LOQ 10 ng L-1 [40] 
Tilidine, nortilidine, 
and bisnortilidine 
Serum OASIS WCX  
(10mm×1mm) 
0.2% formic acid (A) and methanol (B) LC-ESI-MS/MS LOQs > 1 ng mL-1 [41] 
Forty-two therapeutic 
drugs and drugs of abuse 
Serum SPE Strata X-CW  
(2mm×20mm, 25 μm) 
0.5% HCOOH in water (A) and 0.5% HCOOH 
in acetonitrile (B) (90/10, v/v) 
UHPLC-ESI-MS/MS LODs > 0.20 ng mL-1 
LOQs > 0.66 ng mL-1 
[42] 
11-nor-Δ9-
tetrahydrocannabinol-9-
carboxylic acid 
Serum HySphere C8 0.1% formic acid (A) and acetonitrile (B) LC-ESI-MS/MS LODs > 0.25 ng mL-1 
LOQs > 5 ng mL-1 
[43] 
Peptides 
Sifuvirtide (anti-HIV 
peptide) 
Plasma C18 SPE  column 
(50mm×2.1mmi.d., 2µmfrits 
0.2% formic acid in water (A), 
acetonitril/methanol (1:1) (B) (70:30) 
LC-MS/MS 6.1 ng mL-1 [44] 
Aggrecan fragments 
(peptide) 
Urine and Human 
sinovial fluid 
home-prepared immunoaffinity 
columns and  macro peptide-
trapping column 
(Michrom Bioresources, Auburn, 
CA, USA) 
0.1% formic acid in water (A) and 5% 
acetonitrile in water (B) 
LC-MS/MS LOD 2.5  pg mL-1 
(Urine) 
LOD 10  pg mL-1 
(human synovial fluid) 
[45] 
Personal care products 
2-ethylhexyl Human urine HySphere C18 HD  0.2% formic acid in water (A) and 0.2% formic LC-ESI-MS/MS  LODs > 0.1 ng [46] 
4-(N,N-
dimethylamino)benzoate  
(10mm×2mm, 7µm) acid methanol/ acetonitrile (1/1, v/v) (B) LC-ESI-TOF/MS LOQs > 0.3 ng 
Endogenous compounds 
Tryptophan, kynurenine 
and 3-hydroxykynurenine 
Plasma Isolute PRS (propylsulphonic acid 
based strong cation 
exchange)  (10mm×1mm) 
50 mM ammonium formate 
(pH 3) 
LC-ESI-MS/MS LODs > 1 nmol L-1 
LOQs > 23 nmol L-1 
[47] 
Ethinylestradiol Plasma Hysphere C18 HD 
7µm 
Methanol/water (75/25, v/v) LC-APPI-MS/MS LODs > 0.08 pg mL-1 
LOQs > 5 pg mL-1 
[48] 
8-oxo-7,8-dihydro-2′-
deoxyguanosine 
Plasma, urine and 
saliva 
Inertsil ODS-3 column  
(50 mm×4.6 mm, 5 µm) 
50 mL L-1 methanol containing 1 mL L-1 
formic acid (A) and 500 mL L-1 methanol 
containing 1 mL L-1 formic acid (B) 
LC-ESI-MS/MS LODs > 2 fmol [49] 
Eicosanoid inflammation 
biomarkers 
Serum HySphere C18 (EC)  
(10mmx2.0mm, 8 μm) 
methanol/water/ 
acetonitrile/acetic acid (76/22/2/0.02, v/v) 
LC-ESI-MS/MS LODs > 0.09 pg mL-1; 
LOQs > 3 pg mL-1 
[50] 
Serotonin Serum Oasis WCX  
(10 mm×1 mm) 
100 mM ammonium formate (pH 3) (A) and 
acetonitrile (B) 
LC-ESI-MS/MS LOQs > 0.9 nmol mL-1 [51] 
25-Hydroxyvitamin D Serum Waters 5 _m X-Terra 
(2.1 mm×20 mm C18) 
(98:2) methanol:water  
0.1% formic acid and 2 mM ammonium 
acetate(A),   
water with 0.1% formic acid and 2 mM 
ammonium acetate (B) 
LC-MS/MS LOQ 3 nmol L-1 [52] 
Cortisol, cortisone and 
metabolites 
Urine POROS R1/20  
(2.1mm×30 mm, 20 μm particle 
size) 
methanol/acetonitrile (50:50, v/v) (A), and 
water and methanol (50:50, v/v) (B), both 
containing 0.1% formic acid 
LC-ESI-MS/MS -- [53] 
Methylmalonic acid Urine Waters Oasis HLB  
(2.1×20 mm,25 µm) 
1 g L−1 formic acid-acetonitrile/10 mM 
ammonium formiate 60:40 (v/v) 
LC-ESI-MS/MS -- [54] 
Pthalate metabolites Urine Merck C18 trap cartridge 
(2.0 x 55-mm, 3µm, , 
0.001% formic acid in H2O (A), metanol (B) LC-MS/MS LOD 0.2-2 ng mL-1 [55] 
Cortisol and cortisone  Human saliva HySphereTM C18 HD  
(2 mm 10mm,   7 μm SPE cartridge 
0.1% (v/v) formic acid in water (A),0.1% (v/v) 
formic acid in methanol (B) (50:50) 
LC-MS/MS LOQ Cotisol 0.75 nM 
 
Cortisone 0.50 nM 
[56] 
8-iso-PGF2α (indicator of 
lipid peroxidation)  
Exhaled breath 
condensate 
C18 Inertsil ODS  
(33.3mm×4.6mm, 5µm) column 
 
 1% acetonitrile, v/v with 0.1% formic 
acid)(A), 90% acetonitrile, v/v with 0.1% 
formic acid (B) (85:15) 
LC-MS/MS LOD 1  pg mL-1 [57] 
Pollutants 
Chlorpyrifos and 
cypermethrin 
Plasma Hypersil GOLD C8  
(20mm×2.1 mm, 1.9µm) 
20 mM ammonium acetate aqueous solution 
and 
methanol (10:90, v/v)  
LC-ESI-MS/MS LODs > 0.01 ppb [58] 
Perfluorinated compounds Plasma Poros HQ  
(2.1mm×30mm, 10µm) 
0.01% NH4OH solution in 5mM ammonium 
acetate (A) and 0.01% NH4OH solution in 
acetonitrile (B) 
UHPLC-ESI-MS/MS LODs > 3 ng L-1 
LOQs > 10 ng L-1 
MDLs > 9 ng L-1 
[59] 
Polyfluorinated 
compounds 
Serum Polaris C18 HD  
(2mm 10mm) 
20mM ammonium 
acetate (pH 4) in water (A), acetonitrile (B) 
LC-MS/MS LOD 0.1- 0.2  ng mL-1 [60] 
Polyfluorinated 
compounds 
Serum and human 
breast milk 
Oasis®  HLB, 
(2.1mm×20mm 25µm) 
38% 2mMammonium acetate buffer adjusted 
to pH 5 with acetic acid (A), 62% methanol 
(B)  
LC-MS/MS 0.1 to 0.4µg L-1 
(serum) 
0.02 to 0.15µg L-1 
(human breast milk) 
[61] 
Intermediates of  the 
tricarboxylic acid cycle  
Pig and mouse heart 
tissue 
Phenomenex C8 SPE cartridge  
(4 mm x 2 mm, 5 µm) 
 
 98% water, 2% acetonitrile and 0.1% 
formic acid (A),  (98%  acetonitrile, 2% water 
and 0.1% formic acid (B) 
LC-ESI-MS LOD 12-1000 nM [62] 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Table 2. Use of turbulent flow chromatography in bioanalysis. Selected references from 2009-up-to-date. 
 
Target compounds Class Matrix TFC Column 
Flow-rate 
Injection Volume 
Detection LOQ Reference 
Sirolimus and 
everolimus 
Immunosuppressant Whole blood 
50 x 0.5 mm, 50 µm 
Cyclone 
(Thermo Fisher Scientific) 
2.0 mL min-1 
50 µL 
APCI-MS/MS 0.5 ng mL-1 [106] 
453 Drugs 
General - toxicological 
screening 
Urine and serum 
50 x 0.5 mm, 60 µm 
Cyclone and C18 XL 
(Thermo Fisher Scientific) 
2.0 mL min-1 
100 µL 
APCI-MSn - [107] 
Perfluorinated 
compounds 
Perfluorinated compounds Human hair and urine 
50 x 0.5 mm, 60 µm 
Cyclone and C18 XL 
(Thermo Fisher Scientific) 
1.5 mL min-1 
20 µL 
ESI-MS/MS 0.06-13.34 ng g-1 [108] 
25-OH D2/D3 Vitamins Serum 
Cyclone P 
50 x 1.0 mm 
(Thermo Fisher Scientific) 
4.0 mL min-1 
100 µL 
APCI-MS/MS 
4.6 nmol L-1 (25-OHD3) 
3.0 nmol L-1 (25-OHD2) 
[109] 
- Metabonomic studies Plasma 
50 x 0.5 mm, 50 µm 
Cyclone 
(Thermo Fisher Scientific) 
1.25 mL min-1 
10 µL 
ESI-MS - [104] 
Busulfan 
Alkylating antineoplastic 
agent 
Plasma and serum 
Cyclone P 
50 x 0.5 mm 
(Thermo Fisher Scientific) 
1.5 mL min-1 
50 µL 
ESI-MS/MS 0.15µmol L-1 [110] 
9 TKIs and 
metabolites 
Tyrosine kinase inhibitors Plasma and serum 
50 x 0.5 mm, 50 µm 
Cyclone 
(Thermo Fisher Scientific) 
2.0 mL min-1 
100 µL 
APCI-MS/MS 1-10 ng mL-1 a [111] 
Creatinine Creatinine Serum 
50 x 0.5 mm 
Cyclone MCX 
(Thermo Fisher Scientific) 
1.5 mL min-1 
20 µL 
ESI-MS/MS 0.20 mg dL-1 [112] 
- Pharmacokinetics 
Plasma and 
hepatocytes  
50 x 0.5 mm, 60 µm 
Cyclone 
(Thermo Fisher Scientific) 
1.25 mL.min-1 
20 µL 
ESI-MS/MS - [113] 
356 Drugs and 
metabolites 
General - toxicological 
screening 
Urine 
50 x 0.5 mm, 60 µm 
Cyclone and C18 XL 
(Thermo Fisher Scientific) 
2.0 mL min-1 
100 µL 
APCI-MSn 
b 10 ng L-1 (60%) 
100 ng L-1 (90%) 
1000 ng L-1 (100%) 
 
[114] 
Amitriptyline 
Desipramine 
Imipramine 
Nortriptyline 
 
Tricyclic Antidepressants Serum 
Cyclone P 
50 x 0.5 mm 
(Thermo Fisher Scientific) 
2.0 mL min-1 
10 µL 
ESI-MS/MS 6-18 ng mL-1 [115] 
Metanephrine and 
Nometanephrine 
 
Metanephrines 
 
 
Plasma 
50 x 0.5 mm 
MCX-2 
(Thermo Fisher Scientific) 
2.0 mL min-1 
100 µL 
ESI-MS/MS 6.3-12.6 pg mL-1 [116] 
Verticine 
Verticinone 
Isoverticine 
Drugs Plasma 
20 x 2.1 mm, 25 µm 
Oasis HLB 
(Waters) 
4.0 mL min-1 
50 µL 
ESI-MS 0.12-0.595 ng mL-1 [117] 
19 drugs and 
metabolites 
Drugs Urine 
50 x 0.5 mm 
Cyclone P and Cyclone P 
(Thermo Fisher Scientific) 
2.0 mL.min-1 
100 µL 
ESI-MS/MS 5-25 ng mL-1 [118] 
a Reported as limit of accurate measurement (signal at least five times the SD of the background noise) 
b Reported as limited of identification  
 
  
 Table 3. UHPLC bio-analytical applications using sub-2 µm particle size packed columns. 
 
Target compounds Sample matrix Column / Stationary 
phase/Temperature 
Mobile phase / Flow-rate Mass spectrometry Analysis 
time 
Reference 
JAK2 inhibitor 
CYT387 
Plasma  Acquity UPLC BEH C18 
(30 mm x 2.1 mm, 1.7 µm) 
40 oC 
Gradient elution: 
A) 0.005% formic acid solution in water 
B) 0.05 % formic acid solution in methanol 
0.6 mL min-1 
HESI(+) 
Triple quadrupole 
SRM acquisition mode 
1.3 min [133] 
 
 
Ketoconazole Plasma Acquity UPLC  BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
Isocratic elution: 
Water:acetonitrile 44:56 (v/v) with 0.1% 
ammonium hydroxide and 10 mM ammonium 
bicarbonate 
1.0 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
20 s [134] 
 
Vitamin D 
metabolites 
Plasma Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm 
Gradient elution: 
A) 0.1% formic acid in water (5 mM methylamine) 
B) 0.1% formic acid in methanol 
0.3 mL min-1 
ESI(+) 
Triple quadrupole-linear ion trap 
SRM acquisition mode 
2.2 min [135] 
 
Anticancer PR-104 
and metabolites 
Plasma Zorbax Eclipse XDB-C18 
(50 mm x 2.1 mm, 1.8 µm) 
Gradient elution: 
A) 0.01% formic acid in water 
B) acetonitrile 
0.5 mL min-1 
Positive ESI-APCI combined mode 
Triple quadrupole 
SRM acquisition mode 
3.1 min [136] 
 
Small-molecule 
complements in 
Biological system 
Plasma Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
40 oC 
Gradient elution: 
Extracts reconstituted in formic acid 
A) 0.1% formic acid in water 
B) 0.1% formic acid in methanol 
Extracts reconstituted in ammonium bicarbonate 
A) 6.5 mM ammonium bicarbonate in water, pH 8 
B) 6.5 mM ammonium bicarbonate in 
methanol:water 95:5 (v/v)  
0.35 mL min-1 
ESI(+) and ESI(-) 
Linear ion trap MS 
SRM acquisition mode 
 
Accurate mass measurements 
Hybrid LTQ-FTICR M 
(Resolving power 50,000 FWHM) 
8 min [137] 
 
Pravastatin 
Pravastatin lactone 
Plasma 
Urine 
Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
35 oC 
Gradient elution: 
A) 1 mM ammonium acetate pH 4.0 
B) acetonitrile 
0.2 mL min-1 
ESI polarity switching mode 
Triple quadrupole 
SRM acquisition mode 
2 min [138] 
 
Tectorigenin, irigenin 
and irisfloretin 
Plasma 
Urine 
Zorbax SB-C18 
(50 mm x 2.1 mm, 1.8 µm) 
Gradient elution: 
A) 0.1% formic acid in water 
B) acetonitrile 
0.4 mL min-1 
ESI(-) and ESI(+) 
Triple quadrupole 
SRM acquisition mode 
6 min [139] 
 
Octreotide Plasma Acquity UPLC BEH C18 
(100 mm x 2.1 mm, 1.7 µm) 
 
Gradient elution: 
A) 0.1% formic acid in water 
B) 0.1% formic acid in acetonitrile 
0.25-0.3 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
5 min [66] 
 
Clopidogrel active 
metabolite isomers 
Plasma Shim-pack XR-ODS II 
(75 mm x 2.0 mm, 2.2 µm) 
Gradient elution: 
A) 2 mM ammonium acetate-0.2% formic acid in 
water 
B) 2 mM ammonium acetate-0.2% formic acid in 
acetonitrile 
0.5 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
7 min [140] 
 
Eicosapentaeonic acid Plasma Acquity UPLC BEH C18 Gradient elution: ESI(-) 1.3 min [141] 
and docosahexenoic 
acid 
(50 mm x 2.1 mm, 1.7 µm) 
60 oC 
A) 2 mM ammonium acetate pH 4 
B) acetonitrile 
1 mL min-1 
Triple quadrupole 
SRM acquisition mode 
 
Cortisol, cortisone, 
prednisolone, 
dexamethasone and 
11-deoxycortisol 
Plasma, plasma 
ultrafiltrate, 
urine and saliva 
Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
 
Gradient elution: 
A) 2 mM ammonium acetate – 0.1 % formic acid in 
water 
B) 2 mM ammonium acetate – 0.1% formic acid in 
methanol 
0.4 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
2.5 min [142] 
 
Nitrofuran 
metabolites 
Plasma Acquity UPLC BEH C18 
(100 mm x 2.1 mm, 1.7 µm) 
65 oC 
Gradient elution: 
A) 0.5 mM ammonium acetate in water 
B) methanol 
0.5 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
3 min [143] 
 
Testosterone and 
testosterone enanthate 
Plasma Hypersil Gold C18 
(50 mm x 2.1 mm, 1.9 µm) 
45 oC 
Gradient elution: 
A) 2 mM ammonium formate in water 
B) methanol 
0.5 mL min-1 
HESI(+) 
Triple quadrupole 
SRM acquisition mode 
4.5 min [144] 
 
Anandamide and 
related 
acylethanolamides 
Human seminal 
plasma 
Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
 
Gradient elution: 
A) 2 mM ammonium formate containing 0.1% 
formic acid and 5% acetonitrile 
B) 0.1% formic acid in acetonitrile 
0.7 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
3 min [145] 
 
Diuretic and stimulant 
compounds 
Urine Zorbax SB-C8 
(50 mm x 2.1 mm, 1.8 µm) 
Gradient elution: 
A) 1 mM ammonium acetate – 0.001% acetic acid 
in water 
B) 1 mM ammonium acetate -  0.001% acetic acid 
in methanol 
0.3 mL min-1 
ESI polarity switching mode 
HRMS Orbitrap 
8 min [146] 
 
Anabolic steroids Urine Acquity UPLC BEH C18 
(100 mm x 2.1 mm, 1.7 µm) 
 
Gradient elution: 
A) 5 mM ammonium formatted pH 3 in water 
B) 0.1% formic acid in acetonitrile 
0.4 mL min-1 
HESI(+) 
Triple quadrupole 
SRM acquisition mode 
8 min [147] 
 
Cardiovascular drugs, 
polyphenols and 
metabolites 
Urine Hypersil Gold C18 
(100 mm x 2.1 mm, 1.9 µm) 
25 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) acetonitrile 
0.65-0.7 mL min-1 
ESI(+) and ESI(-) 
Triple quadrupole-linear ion trap  
SRM acquisition mode 
8 min [148] 
 
Therapeutic drugs and 
drugs of abuse 
Urine Zorbax Eclipse XDB-C18 
(50 mm x 4.6 mm, 1.8 µm) 
55 oC 
Gradient elution: 
A) 0.5% formic acid in water 
B) 0.5% formic acid in acetonitrile 
0.9 mL min-1 
ESI(+) 
QTrap MS 
SRM acquisition mode 
6 min [42] 
 
Thireostats Urine Acquity UPLC HSS T3 
(high strength silica particles) 
(100 mm x 2.1 mm, 1.8 µm) 
25 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) 0.1% formic acid in methanol 
0.3 mL min-1 
HESI(+) 
Triple quadrupole 
SRM acquisition mode 
6.5 min [149] 
 
Rifamicyn 
isonicotinyl 
hydrazone (HYD) 
Plasma, urine 
and faeces 
Zorbax Eclipse C18 
(50 mm x 4.6 mm, 1.8 µm) 
Gradient elution: 
A) 10 mM ammonium acetate in water 
B) acetonitrile 
0.5 mL min-1 
ESI(+) 
Linear ion trap MS 
SRM acquisition mode 
 
5 min [150] 
 
2-tert-
butylprimaquine (anti-
Plasma Hypersil Gold C18 
(50 mm x 2.1 mm, 1.9 µm) 
Gradient elution: 
A) 20 mM ammonium acetate 
ESI(+) 
Linear ion trap MS 
4 min [151] 
 
malarial compound)  B) acetonitrile 
0.45 mL min-1 
SRM acquisition mode 
 
Doxorubicin and 
daunorubicin 
Liver tumors Shimadzu Shim-Pack ODS 
(50 mm x 2.0 mm, 1.6 µm) 
Gradient elution: 
A) 5 mM ammonium acetate (pH 3.5) in water 
B) acetonitrile 
0.5 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
1.1 min [152] 
 
Anti-tumoral alkyl 
lysophospholipid 
edelfosine 
Plasma, tissue, 
tumor and lipid 
nanoparticulate 
systems 
Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
50 oC 
Isocratic elution: 
1% formic acid aqueous solution:methanol 5:95 
(v/v) 
0.5 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
4 min [153] 
 
Neurotransmitters Brain tissue Acquity UPLC BEH C18 
(50 mm x 2.1 mm, 1.7 µm) 
 
Gradient elution: 
A) 0.05% formic acid and 1 mM 
heptabluorobutyric (HFBA) acid in water 
B) methanol 
0.2 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
4 min [154] 
 
Atorvastatin and its 
metabolites 
Serum Acquity UPLC BEH C18 
(100 mm x 2.1 mm, 1.7 µm) 
35 oC 
Gradient elution: 
A) 0.5 mM ammonium acetate (pH 4.0) in water 
B) acetonitrile 
0.25 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
3.5 min [155] 
 
Emodin Plasma from 
digestive 
segments 
Acquity UPLC BEH C18 
(100 mm x 2.1 mm, 1.7 µm) 
35 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) methanol 
0.3 mL min-1 
ESI(-) 
Triple quadrupole 
SRM acquisition mode 
4 min [156] 
 
Perfluorochemicals Plasma and 
serum 
Zorbax Eclipse XDB-C18 
(50 mm x 4.6 mm, 1.8 µm) 
55 oC 
Gradient elution: 
A) 0.01% NH4OH, 5 mM ammonium acetate in 
water 
B) 0.01% NH4OH in acetonitrile 
1 mL min-1 
ESI(-) 
QTrap MS 
SRM acquisition mode 
5 min [59] 
 
Chlorpyrifos and 
cypermethrin 
Cord blood 
plasma 
Hypersil Gold C18 
(50 mm x 2.1 mm, 1.9 µm) 
Gradient elution: 
A) 20 mM ammonium acetate in water 
B) methanol 
0.3 mL min-1 
HESI(+) 
Triple quadrupole 
SRM acquisition mode 
5 min [58] 
Prohibited drugs in 
doping control 
Dried blood 
spots 
Hypersil Gold C18 
(50 mm x 2.1 mm, 1.9 µm) 
Gradient elution: 
A) 0.2% formic acid in water 
B) acetonitrile 
0.2 mL min-1 
HESI(+) and HESI(-) 
Quadrupole-Orbitrap 
Full scan and all-ion fragmentation 
full scan acquisition modes 
11 min [157] 
 
 
 
 
  
 
Table 4. Bio-analytical applications using porous shell column technology. 
 
Target compounds Sample matrix Column / Stationary 
phase/Temperature 
Mobile phase / Flow-rate Mass spectrometry Analysis time Reference 
Glutathione-trapped 
reactive metabolites 
Plasma Kinetex C18 
(100 mm x 2.1 mm, 2.6 µm) 
 
Gradient elution: 
A) 0.1 % formic acid in water 
B) 0.1% formic acid in acetonitrile 
0.4-0.6 mL min-1 
HESI(+) and HESI(-) 
Linear ion trap-Orbitrap HRMS 
SIM acquisition mode and 
FTMS or ITMS data dependent 
scan of MS2 spectra 
10 min [161] 
 
Isoliquiritigenin 
metabolites 
Urine Agilent Poroshell EC-C18 
(100 mm x 2.1 mm, 2.7 µm) 
40 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) 0.1% formic acid in acetonitrile 
0.4 mL min-1 
ESI(+) and ESI(-) 
TOF MS 
 
12 min [162] 
 
Oseltamivir and 
oseltamivircarboxylate 
Dried blood 
spots 
Ascentix Express C18 
(100 mm x 2.1 mm, 2.7 µm) 
30 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) 0.1% formic acid in methanol 
0.35 mL min-1 
ESI(+) 
QTrap MS 
SRM acquisition mode 
3.5 min [163] 
 
Bromo-guanosine, 
labetalol, reserpine 
and SB243213A (drug 
compound) 
Plasma Ascentix Express C18 
(50 mm x 2.1 mm, 2.7 µm) 
40 oC 
Gradient elution: 
A) 0.1% formic acid in water 
B) 0.1% formic acid in acetonitrile 
1.1 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
0.8 min [160] 
 
Drugs of abuse Oral fluid Kinetex C18 
(100 mm x 2.1 mm, 2.6 µm) 
40 oC 
Gradient elution: 
A) 0.05% formic acid and 5 mM ammonium 
formiate in water 
B) 0.1% formic acid in methanol:acetonitrile 1:1 
(v/v) 
0.5 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
8 min [164] 
 
Imipramine and 
desipramine 
antidepressants 
Plasma Halo fused-core C18 
(30 mm x 2.1 mm, 2.7 µm) 
Gradient elution: 
A) 10 mM ammonium acetate and 0.1% NH4OH 
in water (pH 8.5) 
B) 10 mM ammonium acetate, 0.1% NH4OH and 
0.2% (morpholine or triethylamine) in 
acetonitrile 
0.4 mL min-1 
ESI(+) 
Triple quadrupole 
SRM acquisition mode 
2.5 min [165] 
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